Clinical trials: copd or chronic obstructive
Inflammatory Diseases
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.
The purpose of the study is to assess the safety and tolerability of AZD6793 suspension following oral administration of Single Ascending Dose (SAD) [Part 1] and Multiple Ascending Dose (MAD) [Part 2] in healthy participants.
- Trial name
- NCT05662033
- Testing
- AZD6793
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol.
- Trial name
- EOS (NCT00313209)
- Testing
- Roflumilast
- Where
- 134 sites in Austria, Belgium and 8 more
- Volunteers
- 933 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.
The present trial is conducted to further assess the efficacy by means of serial spirometry, safety and tolerability of three doses of aclidinium bromide administered twice a day compared to previously approved BID drug…
- Trial name
- NCT01120093
- Testing
- Aclidinium bromide 100 μg bid, Aclidinium bromide 200 μg bid, Aclidininum bromide 400 μg bid
- Where
- 11 sites in Belgium, Germany
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment
This study will assess the safety and pharmacokinetics of inhaled GSK573719 and GSK573719/vilanterol combination in healthy subjects and in subjects with severe renal impairment.
- Trial name
- NCT01571999
- Testing
- Inhaled GSK573719, Inhaled GSK573719/vilanterol
- Where
- 2 sites in Czechia, Hungary
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Chronic Obstructive Pulmonary Disease
A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan
The purpose of this study is to evaluate the safety and efficacy of Symbicort Turbuhaler compared to standard COPD treatment during one year in Japanese patients with COPD.
- Trial name
- NCT01070784
- Testing
- Symbicort Turbuhaler (Budesonide/formoterol), Drug: any available COPD treatment; investigator to decide
- Where
- 17 sites in Japan
- Volunteers
- 328 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®
Primary objective is to evaluate time to onset of effect of formoterol, 9 μg single dose,compared with salmeterol, 50 μg single dose, in patients with moderate COPD.Forced Expiratory Volume in 1 second (FEV1) measured by…
- Trial name
- NCT01048333
- Testing
- Formoterol, Salmeterol
- Where
- 17 sites in Italy, Spain and 1 more
- Volunteers
- 109 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients
The primary objective of this study is to assess the effect of umeclidinium/vilanterol (UMEC/VI) versus tiotropium/olodaterol (TIO/OLO) in subjects with moderated COPD.
- Trial name
- NCT02799784
- Testing
- UMEC/VI, TIO/OLO, Albuterol/salbutamol
- Where
- 35 sites in United States, Germany and 2 more
- Volunteers
- 236 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis, Chronic Obstructive Pulmonary Disease
A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
This is a randomized, double-blind, cross-over, vehicle-controlled study to determine whether GS-5737 in 2.8% saline accelerates mucociliary clearance (MCC) in healthy subjects, compared to vehicle of 2.8% saline alone.
- Trial name
- NCT01793649
- Testing
- GS-5737
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Headache, Migraine
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine
This is a double blind placebo-controlled study which will evaluate the efficacy of bupivacaine compared to saline, delivered by the Tx360® device to the sphenopalatine ganglion (SPG), to treat chronic migraine headache.
- Trial name
- NCT03337620
- Testing
- Tx360
- Where
- 11 sites in United States
- Volunteers
- 174 people
- Sponsor
- Tian Medical Inc.
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
- Trial name
- NCT00793624
- Testing
- Olodaterol (BI 1744), Formoterol
- Where
- 93 sites in Argentina, Brazil and 18 more
- Volunteers
- 906 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)
DUS1 and DUS2 are descriptive drug utilisation studies in new users of aclidinium bromide in Europe. The objectives of DUS1 and DUS2 are to describe the characteristics and patterns of use of new users of aclidinium bromide…
- Trial name
- DUS1/DUS2 (NCT03333018)
- Testing
- Aclidinium bromide, Aclidinium bromide/formoterol, Other COPD medication
- Where
- 3 sites in Denmark, Germany and 1 more
- Volunteers
- 22,155 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)
Patients with chronic obstructive pulmonary disease (COPD) have elevated risk of mortality and cardiopulmonary events, particularly following exacerbations.
- Trial name
- SKOPOS:MAZI (NCT06744374)
- Testing
- BGF, MITT
- Where
- United States
- Volunteers
- 22,369 people
- Sponsor
- AstraZeneca
Chronic Spontaneous Urticaria
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
- Trial name
- NCT02649218
- Testing
- Ligelizumab
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Crossover Study in the Treatment of Patients With COPD
The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol [2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and…
- Trial name
- NCT00462540
- Testing
- Formoterol Fumurate inhalation solution 20 mcg, Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Dey
Asthma
Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.
This is a comparative bioavailability study to compare the pharmacokinetics and pharmacodynamic effects of Fluticasone propionate and Salmeterol delivered in a capsule-based inhaler versus a multi-dose dry powder inhaler in…
- Trial name
- NCT01494610
- Testing
- SERETIDE Rotacaps, SERETIDE Diskus
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to demonstrate the clinical equivalence of formoterol-HFA pMDI 12µg/actuation administered twice daily to formoterol DPI 12µg/capsule delivered by the Aerolizer inhaler and administered twice daily in…
- Trial name
- NCT00972140
- Testing
- Formoterol
- Where
- Poland
- Volunteers
- 457 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to evaluate the efficacy of Helium/Oxygen (He/O2) 78%/22% compared to a conventional Air/O2 mixture in reducing endotracheal intubation rate and mortality in patients with severe hypercapnic…
- Trial name
- ECHO/ICU (NCT01155310)
- Testing
- Helium/Oxygen 78%/22%, Air/Oxygen
- Where
- 16 sites in Belgium, France and 4 more
- Volunteers
- 446 people
- Sponsor
- Air Liquide Santé International
COPD, Cachexia
Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in COPD Cachexia
SF-K002 is a pilot study in patients with moderate to severe COPD suffering from involuntary weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective is to study the safety and tolerability of…
- Trial name
- NCT02442908
- Testing
- Nutrifriend Cachexia
- Where
- 4 sites in Sweden
- Volunteers
- 45 people
- Sponsor
- Smartfish AS
Chronic Obstructive Pulmonary Disease
A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)
Randomized study of single and multiple doses of BBT002 in healthy volunteers and in adult patients with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT06944925
- Testing
- BBT002
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.